News
Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods
Leucid Bio: Joint Development Agreement with 4basebio PLC for…
EXACT THERAPEUTICS AS PROVIDES STRATEGIC BUSINESS UPDATE
Plans to recommence enrolment in the ACTIVATE clinical trial…
Calliditas Interim Report Q3, 2021
A quarter of deal making and regulatory review
“Following…
Novo Holdings and Lundbeckfonden Portfolio Company IO Biotech Closes Initial Public Offering on the Nasdaq Global Market
Incubated and supported by Denmark’s largest biotech investors,…
Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics
Asgard Therapeutics developing in vivo immune cell reprogramming…
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected…
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
LONDON, 08 November 2021: Arix Bioscience plc ("Arix", LSE:…
Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
LONDON, 8 November 2021: Arix Bioscience plc ("Arix" or the…
Destiny Pharma’s SAB Member Professor Dale Gerding is Keynote Speaker at C. diff. International Conference
Brighton, United Kingdom – 4th November 2021 – Destiny…
Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference
VMB-100 shows therapeutic potential in Stress Urinary Incontinence
…
Phebra Acquires Equity Stake in UK Specialty Hospital Pharma Company Flexipharm Austrading
- Phebra takes part ownership of Flexipharm Austrading through…
Verona Pharma Announces November 2021 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona…
Muna Therapeutics appoints Dr. Niels Plath as Chief Scientific Officer
Brings more than 15 years of CNS drug discovery and development…
Arix Bioscience: Aura Biosciences prices Nasdaq IPO
LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, "Arix"),…
eTheRNA immunotherapies conference attendance for November 2021
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage…
Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs
Winning scientific poster shows complete tumor regression…
Futura Medical plc Board Appointment
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Synendos Therapeutics Appoints Scientific Advisory Board
Synendos Therapeutics is thrilled to announce the formation of…
Synendos Therapeutics Appoints Scientific Advisory Board
Synendos Therapeutics is thrilled to announce the formation of…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
